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Abstract
Background: Infection of dogs with the cardiopulmonary nematode Angiostrongylus vasorum may result in severe
clinical disease therefore adequate prevention is necessary. A randomized, negative control, blinded study was
conducted to evaluate the efficacy in the prevention of canine A. vasorum infection after monthly administrations
of NexGard Spectra®, a novel chewable tablet formulation combining the insecticide and acaricide afoxolaner and
the anthelmintic milbemycin oxime, in a multiple challenge (trickle infection) model.
Methods: Twenty beagle dogs were challenged orally with doses of approximately 32–43 third-stage larvae of A.
vasorum once every other week on seven occasions (Study Days -7, 7, 21, 35, 49, 63 and 77). Ten dogs were
administered NexGard Spectra® as close as possible to the minimum recommended dose of afoxolaner and
milbemycin oxime, i.e. 2.5 mg/kg body weight and 0.5 mg/kg body weight, respectively, four times at monthly
intervals (Study Days 0, 28, 56 and 84) while the remaining ten dogs served as untreated controls. For parasite
recovery and count, dogs were euthanized humanely and necropsied six to eight days following the last treatment
(Study Days 90–92). Beginning six weeks after first inoculation, faeces were collected on a bi-weekly basis and
examined for first-stage larvae of A. vasorum.
Results: Untreated dogs harboured 39–95 adult A. vasorum (geometric mean, 66.4), while zero to 24 adult A.
vasorum were recovered from the treated dogs (geometric mean, 3.4; P < 0.0001). Thus, efficacy of NexGard
Spectra® administered at monthly intervals against incoming A. vasorum was 94.9 %. Compared to the untreated
controls, larval excretion of the treated dogs was reduced by 99.9 % (P < 0.0001).
Conclusion: Results of this study demonstrate that NexGard Spectra®, when administered at monthly intervals, can
effectively prevent canine A. vasorum infection.
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Background
Parasitic nematode infections of the cardiopulmonary
organs of dogs have received increasing attention by
both practising veterinarians and parasitologists in re-
cent years. For more than two decades, canine angio-
strongylosis has expanded its geographical distribution
and appears to occur with increasing prevalence in
Europe [1–3]. In certain regions of Denmark, Germany,
Hungary, France, Ireland, Italy, the Netherlands, Poland,
Portugal, Sweden and Switzerland, canine angiostrongy-
losis is considered to be endemic [1–5]. In the United
Kingdom, hyper-endemic foci have been identified where
practitioners reported more than 20 cases per year.
Veterinary practices in those areas are 15 to 16 times
more likely to see clinical angiostrongylosis than any-
where else [2, 3, 6].
Canine angiostrongylosis is caused by the nematode,
Angiostrongylus vasorum. The parasite, first described in
France in the 19th Century [7], is commonly known as
“canine lungworm” or “French heartworm”. Adult A.
vasorum reside in the right heart and pulmonary arterial
tree of dogs and other canids. As most members of the
superfamily Metastrongyloidea, A. vasorum has an indir-
ect life-cycle with canids as the definitive host, terrestrial
gastropods (mainly slugs) as intermediate hosts, and
frogs acting as paratenic or intermediate hosts [8]. Adult
female nematodes release eggs which are carried to the
pulmonary capillaries where they are trapped. First-stage
(L1) larvae hatching from the eggs enter the alveoli, pass
through the tracheobronchial tree, pharynx, gastrointes-
tinal tract, and are excreted in the faeces. Dog faeces are
an attractive food for many gastropod molluscs [9] in
which the larvae develop to become infectious for the
final host. In common, with most metastrongyloid nem-
atodes, A. vasorum seems to display little or no specifi-
city with respect to their molluscan intermediate hosts
[10]. Dogs become infected by ingestion of intermediate
or paratenic hosts containing the infectious third-stage
(L3) larvae. Following ingestion by a canid, larvae pene-
trate the intestinal wall, enter the visceral lymph nodes
and are then carried via the hepatic portal vein to the
heart and pulmonary arterial system where first imma-
ture worms arrive 10 days following infection and de-
velop into mature adults [10, 11]. The prepatent period of
canine A. vasorum infection appears to vary considerably
[9]. However, in recently reported studies, excretion of L1
larvae was observed to commence in most dogs six to
eight weeks after single challenge infection [12–14].
Angiostrongylosis may substantially impact the health
of infected dogs and is potentially life-threatening. In-
fection of dogs with A. vasorum may be asymptomatic;
however, this is not the rule [15]. The disease may re-
sult in variable clinical conditions, ranging from mild
manifestations to severe forms. Cardio-respiratory signs
including cough, exercise intolerance and loss of condi-
tion are the most common clinical manifestations, with
coagulation disorders being less common but more
likely to be fatal [3, 16]. The course of the infection is
often chronic and subtle and therefore owner may
become aware only when severe conditions such as co-
agulopathies or neurological disorders occur, with fre-
quently fatal outcome [12].
In this context, effective measures to prevent the in-
fection are of great interest for dog owners and veteri-
narians in areas where A. vasorum is endemic. Currently,
only a few veterinary products are licensed for A. vasorum
prophylaxis if used at monthly intervals.
The present study was conducted to evaluate the effi-
cacy of monthly administrations of the macrocyclic lac-
tone milbemycin oxime in the prevention of canine A.
vasorum infection, when administered in a novel chew-
able tablet formulation in combination with the isoxazo-
line afoxolaner (NexGard Spectra®).
Methods
This controlled study was conducted in compliance
with the international Cooperation on Harmonisation
of Technical Requirements for Registration of Veterin-
ary Medicinal Products (VICH) Guideline (GL) 9, enti-
tled Good Clinical Practice and was in general
accordance to VICH GL7, “Efficacy of Anthelmintics:
General Requirements” [17], VICH GL19, “Efficacy of
Anthelmintics: Specific Recommendations for Canines”
[18] and the “World Association for the Advancement
of Veterinary Parasitology (WAAVP) guidelines for
evaluating the efficacy of anthelmintics for dogs and
cats” [19]. The protocol of the study has been reviewed
and approved by the Merial Institutional Animal Care
and Use Committee and was in compliance with the
local animal welfare legislation. All personnel involved
in collection of efficacy data, health observations and
physical examinations were blinded to the treatment
assignment of the animals.
Animals and study design
This study included 20 purpose bred, healthy beagle
dogs of both sexes. Dogs weighed 10.0–16.4 kg and were
nine months old at study start. The animals were group-
housed under identical conditions by sex and treatment
group, except for the individual collection of faeces and
post-treatment health observations. Dogs enrolled in the
study were negative for A. vasorum L1 larvae prior to
the first inoculation as confirmed by the examination of
faeces using the Baermann-Wetzel larval migration tech-
nique [20] and were considered healthy and suitable for
inclusion in the study by a veterinarian.
Prior to first treatment (Study Day -1), dogs were
ranked based on decreasing body weight and randomly
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allocated to two groups of 10 dogs each, untreated (Con-
trol) and treated (NexGard Spectra®). Throughout the
study, animals were observed at least once daily for gen-
eral health.
The A. vasorum strain originated from a naturally in-
fected dog in Denmark and was passaged in foxes and
dogs. A batch of 100+/−2 Helix aspersa snails originated
from a French breeding farm were injected each with
approximately 1,500 first-stage A. vasorum larvae in a
single inoculation. Snails were maintained in a specific
crate within the research center facilities during the
whole duration of the study. Infection of dogs started
6 weeks after snails injection to allow molting of first-
stage A. vasorum larvae into infective third-stage A.
vasorum larvae. Briefly, every other week on seven occa-
sions, starting on study days -7, tissues of 3 or 4 snails
were processed by peptic digestion to recover third-stage
A. vasorum larvae. The larvae were separated from the
digest suspension by sieving followed by sedimentation
and cleaning with tap water. Dogs were inoculated orally
using a syringe with approximately 32, 43, 40, 41, 35, 32
and 37 third-stage larvae of A. vasorum respectively on
days -7, 7, 21, 35, 49, 63 and 77. The total inoculum size
per dog was approximately 260 larvae.
Treatment
The dogs were weighed on the day before each treat-
ment for dose determination and any remaining food
was removed on the day prior to treatment. Dogs allo-
cated to the treated group were dosed orally on Study
Days 0, 28, 56 and 84 with a combination of afoxola-
ner plus milbemycin oxime chewable tablets (NexGard
Spectra®, Merial). Three sizes of chewable tablets were
used (0.5 g, 1 g, and 2 g containing 9.375 mg +
1.875 mg, 18.75 mg + 3.75 mg, and 37.5 mg + 7.5 mg
of afoxolaner plus milbemycin oxime, respectively)
and combined as appropriate in order to achieve dos-
ing of the dogs as close as possible to the minimum
recommended dose of 2.5 mg/kg afoxolaner and
0.5 mg/kg milbemycin oxime.
All dogs were observed for adverse reactions hourly
for four hours after each treatment administration.
Faecal examination
Faeces were collected from each dog on Days 35, 49, 63,
77 and 90, and 10 g samples each were examined for the
excretion of A. vasorum L1 larvae using the Baermann-
Wetzel method.
Clinical follow-up
Throughout the study, animals were observed at least
once daily for general health. Physical examinations in-
cluding determination of heart rate and respiration rate,
auscultation of the lungs, inspection of mucous
membranes (conjunctivae and inner lips) were con-
ducted on Days 31, 55 and 87. In addition, body weight
of all dogs was determined on Days -1, 27, 55, 83 and on
the day of necropsy.
Parasite recovery and count
On Days 90 to 92, dogs were euthanized humanely.
Angiostrongylus vasorum were recovered from the heart
and pulmonary arteries by reverse lung perfusion followed
by dissection as described previously [12]. Liquids col-
lected were strained through a 32 μm mesh size sieve in
order to facilitate the collection of nematodes of various
sizes. All A. vasorum were collected and counted (tails in
the case of fragments). A macroscopical examination of
the lungs was performed during necropsy.
Statistical analysis
The primary endpoint for the treatment effectiveness
claim was the total A. vasorum count including imma-
ture and adult worms. These counts were transformed
to the natural logarithm of (count +1) for calculation of
geometric means for each treatment group. Efficacy for
the treated group was determined for A. vasorum by cal-
culating the percent efficacy as 100[(C-T)/C], where C is
the geometric mean among untreated controls and T is
the geometric mean among the treated animals.
Individual faecal A. vasorum L1 larval counts of sam-
pling Days 35, 49, 63, 77 and 90 were used to calculate
the larval output over the course of the study (determin-
ation of period larval counts between two samplings
using the trapezoidal rule summed up to estimate the
cumulative larval output). Cumulative larval outputs
were transformed as described above for calculation of
geometric means for each treatment group.
For both A. vasorum worm counts and cumulative A.
vasorum larval output, log-counts of the treated group
were compared to the log-counts of the untreated Con-
trol Group using an F-test adjusted for the allocation
blocks used to randomize the animals to the Treatment
Groups. The MIXED procedure in SAS Version 9.4 was
used for the analysis of variance, with the Treatment
Groups listed as a fixed effect, and the allocation blocks
listed as a random effect. All testing was two-sided at
the significance level α = 0.05.
Results
No adverse event or abnormal clinical reaction related
to treatment was observed throughout the study, indi-
cating that the monthly treatment with NexGard Spec-
tra® was well accepted and safe. A mean dose of 0.58 ±
0.04 mg/kg of milbemycin oxime, the anthelmintic active
in the chewable tablet formulation, was administered at
each of the four treatment time-points.
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Angiostrongylus vasorum nematode counts
The counts of A. vasorum collected at necropsy are pre-
sented in Table 1. Angiostrongylus vasorum were recov-
ered from all untreated dogs, with 39 to 95 adult worms
recovered per dogs, corresponding to individual estab-
lishment rates ranging from 15 to 36.5 %. Dogs treated
with NexGard Spectra® harbored 0 to 24 adult A.
vasorum. The geometric mean worm count in the
treated group (3.4) was significantly lower (F(1,9) = 92.61,
P < 0.0001) compared to the geometric mean worm
count in the untreated control group (66.4), and efficacy
of NexGard Spectra® administered at monthly intervals
against incoming A. vasorum was 94.9 %.
Faecal Angiostrongylus vasorum first-stage larval counts
While no larvae were recovered from the faeces col-
lected on Day 35 (i.e. 42 days after first inoculation), two
dogs from the untreated group excreted one and three
larvae per 10 g of faeces collected on Day 49 (i.e. 56 days
after first inoculation). Overall, A. vasorum L1 larvae
were recovered from the faeces collected on Days 49, 63,
77 and 90, of 2/10, 6/10, 9/10 and 10/10 untreated dogs
respectively. Larval counts of the untreated dogs in-
creased over the course of the study and ranged between
2 and 2819 larvae per 10 g of faeces collected on Day 90
(geometric mean, 133.5 larvae/10 g). In contrast, A.
vasorum L1 larvae were only recovered from faeces col-
lected on Days 63 and 90, of 1/10 and 2/10 NexGard
Spectra®-treated dogs with counts ranging between 1
and 25 larvae per 10 g of faeces collected on Day 90
(geometric mean, 0.5 larvae/10 g).
Geometric mean faecal larval counts over the course
of the study are shown in Fig. 1. Total cumulative larval
output, which is represented by the area under the
curves, was reduced by 99.9 % in the NexGard Spectra®-
treated dogs compared with the untreated animals
(1,277.2 larvae/10 g*day vs 1.1 larvae/10 g*day; F(1,9) =
65.46, P < 0.0001).
Clinical signs and gross pathology lesions
Physical examination with special regard to cardiorespi-
ratory signs by determination of heart and respiration
rates, auscultation of the lungs, and inspection of mu-
cous did not reveal any abnormality in any dog and
there was no difference in body weight gain between the
dogs of the two groups over the course of the study.
In-situ inspection of the lungs in open thoracic cav-
ity (prior to reverse perfusion for recovery of the
worms) revealed that lungs of the dogs from the
treated group had a normal external appearance con-
sisting of pink, uniform, smooth surface normal lungs
with limited circumscribed lesions whereas lungs of
the dogs in the untreated dogs displayed changes of
the surface consisting of overall pale beige to brown-
ish yellow areas often associated with multifocal dark
red patches and spots, and marbled and hardened
surface consistent with multifocal hemorrhages areas
and granulomatous pneumonia.
Representative images of lungs of untreated and treated
dogs are presented in Figs. 2 and 3, respectively.
Discussion
Milbemycin oxime has been used in the treatment and
control of canine nematode infections since the early
1990s. Previously reported controlled laboratory and
multi-center field studies testing the efficacy of the oral
afoxolaner plus milbemycin oxime chewable tablet for-
mulation NexGard Spectra® administered once to dogs
have confirmed that milbemycin oxime provides high ef-
ficacy against a broad range of canine adult intestinal
nematode infections and prevents heartworm disease
[21–24]. Results of this study have demonstrated that
monthly administration of NexGard Spectra® to dogs is
highly efficacious in the prevention of A. vasorum
Table 1 Nematode counts and percentage efficacy of monthly
administered NexGard Spectra® against Angiostrongylus vasorum
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infection. This is in accordance with an epidemio-
logical study conducted in an endemic area in the
UK, where anthelmintic treatment, specifically milbe-
mycin oxime, given in the 1–12 weeks before sam-
pling appeared to decrease the chance of testing
positive for A. vasorum [15].
The multiple challenge infection (trickle infection)
model used in this study was designed to better mimic
the natural conditions of infection of dogs. Studies asses-
sing the presence of A. vasorum in gastropod molluscs
have indeed reported not only highly variable prevalence
[25] but also a large variation in the burden of A.
vasorum larvae (range 1–743 per gastropod [12], with
most gastropods harbouring low numbers [12, 26, 27]).
Thus, under natural conditions dogs are likely to get in-
fection through repeated exposure to small numbers of
infectious A. vasorum larvae. On average 26.7 % of the
total inoculum size was recovered as adult and imma-
ture A. vasorum from the untreated animals at necropsy
in this study. This infection rate as well as the larval ex-
cretion eight weeks after the initial inoculation is within
the range of findings from recently reported single point
challenge studies [12, 14, 28]. The short interval between
the latest inoculation and the necropsy was sufficient to
allow the molt of larval stages into immature adults. In-
deed, Rosen et al. [29] showed that A. vasorum complete
Fig. 1 Geometric mean of faecal Angiostrongylus vasorum L1 larval counts (study days 35 to 90)
Fig. 2 a, b Lungs from two dogs of the untreated control group
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their 4th molt (L4 to immature adult) within seven days
after infection in the abdominal lymph nodes of dogs
and that 30 % of A. vasorum immature adults were re-
covered from the right heart/pulmonary arteries
within ten days following infection and 80 % within
14 days following infection [29]. In this latest study,
dogs were younger than in the present one (1.5 to
3.5 months old) but the difference in the age seems
not to have an impact on the development of A.
vasorum since egg shedding (i.e. development of
gravid females) started at a similar time in both stud-
ies (Day 49 in Rosen study; between Day 42 and Day
56 in the present study). Since the interval between
last inoculation and necropsy was 13–15 days in the
present study, the majority of inoculated nematodes
have reached the circulatory system where they can
be readily recovered. In addition, as efficacy calcula-
tion is based on the comparison between numbers of
nematodes recovered from untreated controls and
treated groups, both of which submitted to similar
conditions of infection and necropsy, therefore there
is no bias in the results of efficacy.
Prevention of establishment of A. vasorum in the
treated dogs compared to the untreated animals by al-
most 95 % was accompanied by a reduction of faecal lar-
val shedding of 99.9 %. Thus, monthly administration of
NexGard Spectra® to dogs in A. vasorum endemic areas
has the potential to reduce in magnitude the contamin-
ation of the environment with infectious stages for inter-
mediate hosts which may contribute to lower the risk of
disease transmission.
According to the Medical Agencies worldwide
(Europe, USA, Japan, Australia), the requirements for
approval of an anthelmintic product are based on
significant statistical differences between the treated
and control groups and on calculated percent effect-
iveness of 90 % or more (EMEA-CVMP/VICH/832/
99, 2000). Previous studies evaluating the efficacy of
milbemycin oxime (0.75–1.18 mg/kg body weight)
[14], or moxidectin (2.5 mg/kg) [12] against the
establishment of angiostrongylosis have demonstrated
respectively 98.8 and 100 % reduction of A. vasorum
counts in the lung of treated animals. In those stud-
ies, a single treatment was performed respectively
two days or 30+/−2 days post a single inoculation of
200–250 larvae [12, 14]. These results, along with
those of the present study, corroborate the hypothesis that
monthly administration of lactone macrocyclic would re-
duce the risk of canine angiostrongylosis.
No clinical sign indicative for angiostrongylosis was
observed during clinical examination of any of the
animals from both groups. A similar asymptomatic
pattern in experimentally infected animals has been
previously described in another anthelmintic study
[12] where A. vasorum counts in untreated dogs were
comparable to the numbers recovered from the un-
treated dogs in the present study. In two other ex-
perimental studies, dogs presented respiratory signs
[12, 30] but those signs were only noticed in very few
control animals in one of those studies [12]. The ex-
pression of clinical signs seems therefore to be vari-
able in experimental infection with A. vasorum. The
absence of clinical signs in the untreated dogs in this
study may be related to the short observation period
of 14 weeks following initial inoculation but may also
be related to the limited exercise of the dogs kept in
laboratory conditions.
Conclusion
In conclusion, the results of this study demonstrate
that monthly administrations of NexGard Spectra® is
an effective treatment for the prevention of canine A.
vasorum infection in addition to the proved efficacy
of the chewable tablet formulation in the treatment
and control of infections with major intestinal nema-
todes, fleas and ticks [18, 31] and prevention of
heartworm disease [18]. Administration of NexGard
Spectra® offers a convenient solution for the treat-
ment of dogs at risk of multi-parasitic infections. As
a palatable oral product, NexGard Spectra® is well
Fig. 3 a, b Lungs from two dogs of the NexGard Spectra®-treated group
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suited to favour the medication adherence which is a
critical factor in preventive control programs [32].
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